Quick Answer
4D Molecular Therapeutics, Inc. reported Total Revenue of $85.21 million for fiscal year 2025.
4D Molecular Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $85.21M +230194.6% |
$37.0K -99.8% |
$20.72M +562.3% |
$3.13M -82.7% |
$18.04M +32.5% |
$13.61M +94.8% |
| Revenue (ASC 606) | $85.21M +230194.6% |
$37.0K -99.8% |
$20.72M +562.3% |
$3.13M -82.7% |
$18.04M +35.0% |
$13.36M +92.0% |
| Net Income | -$140.11M +12.9% |
-$160.87M -59.5% |
-$100.84M +6.2% |
-$107.49M -50.7% |
-$71.32M -25.8% |
-$56.69M -15.0% |
| Diluted EPS | -$2.42 +18.8% |
-$2.98 -15.5% |
-$2.58 +22.3% |
-$3.32 -29.2% |
-$2.57 | — |
| Total Assets | $566.71M +1.1% |
$560.38M +64.9% |
$339.89M +29.8% |
$261.85M -25.9% |
$353.49M +22.6% |
$288.33M +395.1% |
| Cash and Equivalents | $60.24M -59.7% |
$149.34M -40.1% |
$249.11M +375.8% |
$52.35M -65.8% |
$153.00M -44.7% |
$276.73M +457.3% |
| Stockholders Equity | $505.66M -1.0% |
$510.61M +65.9% |
$307.83M +33.1% |
$231.34M -27.5% |
$319.11M +24.5% |
$256.39M +451.4% |
| Operating Income | -$159.55M +15.1% |
-$187.84M -66.4% |
-$112.87M -2.6% |
-$110.03M -54.3% |
-$71.33M -25.9% |
-$56.66M -11.6% |
| Shares Outstanding | 57.61M +25.8% |
45.79M +6.3% |
43.08M +32.0% |
32.63M +1.2% |
32.22M +20.8% |
26.68M +415.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $90.0K | +2900.0% | +500.0% |
| Revenue (ASC 606) | September 30, 2025 | $90.0K | +2900.0% | +500.0% |
| Net Income | September 30, 2025 | -$56.88M | -29.7% | -4.1% |
| Diluted EPS | September 30, 2025 | -$1.01 | -27.8% | -3.1% |
| Total Assets | September 30, 2025 | $423.98M | -29.8% | -10.5% |
| Cash and Equivalents | September 30, 2025 | $48.55M | -74.1% | -37.1% |
| Stockholders Equity | September 30, 2025 | $368.98M | -33.3% | -12.3% |
| R&D Expense | September 30, 2021 | $15.84M | +37.1% | +4.1% |
| Operating Income | September 30, 2025 | -$61.19M | -19.7% | -2.9% |
| Shares Outstanding | September 30, 2025 | 46.77M | -10.0% | +0.2% |
- 4D Molecular Therapeutics, Inc. reported Total Revenue of $85.21 million for fiscal year 2025.
- 4D Molecular Therapeutics, Inc. showed an increase of +230194.6% in Total Revenue compared to the prior fiscal year.
- 4D Molecular Therapeutics, Inc. reported Revenue (ASC 606) of $85.21 million for fiscal year 2025.
- 4D Molecular Therapeutics, Inc. showed an increase of +230194.6% in Revenue (ASC 606) compared to the prior fiscal year.
- 4D Molecular Therapeutics, Inc. reported Net Income of -$140.11 million for fiscal year 2025.
- 4D Molecular Therapeutics, Inc. showed an increase of +12.9% in Net Income compared to the prior fiscal year.
- 4D Molecular Therapeutics, Inc. reported Diluted EPS of $2.42 per share (loss) for fiscal year 2025.
- 4D Molecular Therapeutics, Inc. showed an increase of +18.8% in Diluted EPS compared to the prior fiscal year.
- 4D Molecular Therapeutics, Inc. reported Total Assets of $566.71 million for fiscal year 2025.
- 4D Molecular Therapeutics, Inc. showed an increase of +1.1% in Total Assets compared to the prior fiscal year.
- 4D Molecular Therapeutics, Inc. reported Cash and Equivalents of $60.24 million for fiscal year 2025.
- 4D Molecular Therapeutics, Inc. showed a decrease of -59.7% in Cash and Equivalents compared to the prior fiscal year.
- 4D Molecular Therapeutics, Inc. reported Stockholders Equity of $505.66 million for fiscal year 2025.
- 4D Molecular Therapeutics, Inc. showed a decrease of -1.0% in Stockholders Equity compared to the prior fiscal year.
- 4D Molecular Therapeutics, Inc. reported Operating Income of -$159.55 million for fiscal year 2025.
- 4D Molecular Therapeutics, Inc. showed an increase of +15.1% in Operating Income compared to the prior fiscal year.
- 4D Molecular Therapeutics, Inc. reported Shares Outstanding of 57.61 million shares for fiscal year 2025.
- 4D Molecular Therapeutics, Inc. showed an increase of +25.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: